Granzyme B PET/CT predicts chemo-immunotherapy outcomes in microsatellite stable gastric cancers
European Journal of Nuclear Medicine and Molecular Imaging · 2026-05 · 53 (6) · 3817-3826
DOI: 10.1007/s00259-025-07734-w ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 16.01.2026. Verfasst von Qiufang Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, P.R. China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Positron Emission Tomography Computed Tomography, Granzymes, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Shanghai Municipal Health Commission Health Industry Clinical Research Special Project, Natural Science Foundation of Shanghai Municipality, Aeronautical Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Prognostic stratification for microsatellite stable (MSS) gastric cancer (GC) remains challenging. This study evaluated the predictive and prognostic value of [68Ga]Ga-NOTA-GSI PET/CT imaging in a large cohort of MSS GC patients receiving chemo-immunotherapy. METHODS: In this retrospective study, 145 patients with MSS GC underwent [68Ga]Ga-NOTA-GSI PET/CT after two or three cycles of chemo-immunotherapy. Measurements included SUVmax, SUVmean, GSI tumor volume (GSI-TV), total lesion uptake (TLU), tumor-liver ratio (TLR), and tumor-blood ratio (TBR). The study analyzed associations between short-term treatment response (RECIST 1.1 or tumor regression grade score) and progression-free survival (PFS) using receiver operating characteristic (ROC) curves, logistic regression, and Cox proportional hazards models. RESULTS: Responders exhibited significantly higher uptake of [68Ga]Ga-NOTA-GSI than non-responders, including SUVmax, sumSUVmax, and TBR (all P < 0.05) across all patients and various subgroups, while volumetric parameters (GSI-TV, TLU) showed no notable difference. SUVmax was a reliable predictor of response (AUC = 0.755 for all patients; AUC = 0.882 for the neoadjuvant subgroup). In survival analysis, an SUVmax ≥ 2.6 independently predicted significantly longer PFS (median PFS of 14.0 vs. 9.0 months; hazard ratio, 0.673; P = 0.016). CONCLUSION: The study highlighted the significant value of [68Ga]Ga-NOTA-GSI PET/CT in assessing the effectiveness of chemo-immunotherapy and predicting outcomes in MSS gastric cancer patients. Subgroup analysis confirmed its reliable predictive power across neoadjuvant, palliative, and adjuvant treatments, supporting the potential for its broad clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, P.R. China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
- Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, 200032, China.
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai, 200433, China.
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, P.R. China. xxp0012@ustc.edu.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. xxp0012@ustc.edu.
ORCID-Profile: Shaoli Song
Förderung
- Shanghai Municipal Health Commission Health Industry Clinical Research Special Project
- Natural Science Foundation of Shanghai Municipality
- Aeronautical Science Foundation of China
Zitieren
APA
Liu, Q., Yang, Z., Zhang, J., Li, J., Qiao, Y., Hu, S., Liu, X., Xu, X., & Song, S. (2026). Granzyme B PET/CT predicts chemo-immunotherapy outcomes in microsatellite stable gastric cancers. European Journal of Nuclear Medicine and Molecular Imaging, 53(6), 3817-3826. https://doi.org/10.1007/s00259-025-07734-w
Vancouver
Liu Q, Yang Z, Zhang J, Li J, Qiao Y, Hu S, et al. Granzyme B PET/CT predicts chemo-immunotherapy outcomes in microsatellite stable gastric cancers. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(6):3817-3826. doi:10.1007/s00259-025-07734-w
BibTeX
@article{Liu2026,
author = {Liu, Qiufang and Yang, Ziyi and Zhang, Jianping and Li, Jindian and Qiao, Ying and Hu, Silong and Liu, Xiaosheng and Xu, Xiaoping and Song, Shaoli},
title = {Granzyme B PET/CT predicts chemo-immunotherapy outcomes in microsatellite stable gastric cancers},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {6},
pages = {3817--3826},
doi = {10.1007/s00259-025-07734-w}
}
EUVIMED